Mirtazapina Flas Stada (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Stada, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapina Flas Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on central neurotransmitter pathways to alleviate depressive symptoms. - Major depressive disorder: improves mood, sleep, appetite and overall functional capacity.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal ideation, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents - Severe hypotension or syncope - Allergic reactions such as rash, angioedema, or anaphylaxis - Hepatotoxicity or liver enzyme elevations

Before initiating therapy, clinicians should evaluate several safety aspects. - Hepatic function: assess liver enzymes in patients with liver disease - Weight monitoring: track body weight regularly due to potential gain - Suicidal risk: monitor for emergent suicidal thoughts, particularly in early weeks - Elderly patients: use caution because of heightened sedation and fall risk - Discontinuation: avoid abrupt cessation to reduce withdrawal phenomena - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis - Other central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may increase mirtazapine plasma levels - Antihistamines: enhanced anticholinergic effects - Antihypertensives: possible additive blood pressure lowering - Oral contraceptives: may reduce contraceptive effectiveness